SparingVision

Summary

Seedtable Score

50

Locations

• Paris

Company Size

• 1 - 11

Last Stage Round

• Series A

Industry

• Biotech
• Deep Tech
• Health Tech

Insights

SparingVision, a Paris-based biotech company, is developing genomic medicines to treat inherited retinal diseases that cause blindness. By addressing the root genetic causes, they aim to offer more effective and lasting treatments compared to existing therapies that primarily provide symptom relief. This focus potentially gives them an edge in the market. Their B2B model and backing from investors like Ysios Capital position SparingVision as a strong contender in vision preservation and quality-of-life improvements for those affected by genetic retinal disorders.

• Series A (2020-01-01) $52.8M

---

Investors

• Ysios Capital Series A

---